SEC Form 4 · accession 0000899243-16-021566
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas DesRosier
Officer — See Remarks
Period of report
Jun 1, 2016
Accepted (ET)
Jun 2, 2016 · 9:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $30.90 | Jun 1, 2016 | A | 100,000 | A | — | May 31, 2026 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1The option will vest as to 25% of the shares on May 16, 2017. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
Remarks
Chief Legal Officer and Executive Vice President